SYSTEMATIC REVIEW/META-ANALYSIS
Reduced expression of CDH1 and its prognostic value in pancreatic cancer: a meta-analysis
Jing Tian 1, 2,   Yuan Liang Wang 2, 3
 
More details
Hide details
1
Department of Anaesthesiology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China
2
Department of Surgery, Heidelberg University Hospital, Heidelberg, Baden Württemberg, Germany
3
Department of Plastic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China
Submission date: 2020-01-28
Final revision date: 2020-05-07
Acceptance date: 2020-05-22
Online publication date: 2020-06-23
 
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
In this study, we aimed to focus on reduced expression of E-cadherin (CDH1) and its prognostic value in pancreatic cancer (PC) using a meta-analysis.

Material and methods:
For this purpose, the PubMed and EMBASE databases were searched from inception until September 1, 2018. Hazard ratio (HR) and 95% confidence interval (CI) were pooled to evaluate the association between CDH1 expression and overall survival (OS); also, odds ratio (OR) and 95% CI were used to assess the correlation between clinicopathological features and CDH1 expression in PC patients. Data from a total of 1805 patients from 16 articles were used in this meta-analysis.

Results:
PC patients with decreased expression of CDH1 had a shorter OS (HR = 1.25, 95% CI: 1.09–1.41), without a significant heterogeneity (I2 = 27.1%, p = 0.151). The down-regulated expression of CDH1 was strongly associated with tumour grade (OR = 1.80, 95% CI: 1.07–3.03).

Conclusions:
Down-regulated expression of CDH1 has potential as a predictive marker of poor prognosis in PC patients. However, further high-quality and large-scale clinical studies are required to validate our findings.

eISSN:1896-9151
ISSN:1734-1922